메뉴 건너뛰기




Volumn 9, Issue 10, 2009, Pages 2217-2222

Subgroup analyses in randomized controlled trials: The need for risk stratification in kidney transplantation

Author keywords

Kidney transplantation; Outcomes; Prediction models; Risk factors

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

EID: 70349224483     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02802.x     Document Type: Review
Times cited : (13)

References (30)
  • 1
    • 0035857966 scopus 로고    scopus 로고
    • The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials
    • DOI 10.1016/S0140-6736(00)04337-3
    • Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001 357 : 1191 1194. (Pubitemid 32378696)
    • (2001) Lancet , vol.357 , Issue.9263 , pp. 1191-1194
    • Moher, D.1    Schulz, K.F.2    Altman, D.G.3    Lepage, L.4
  • 2
    • 49649089984 scopus 로고    scopus 로고
    • Design and analysis of clinical trials in transplantation: Principles and pitfalls
    • Schold JD, Kaplan B. Design and analysis of clinical trials in transplantation: Principles and pitfalls. Am J Transplant 2008 8 : 1779 1785.
    • (2008) Am J Transplant , vol.8 , pp. 1779-1785
    • Schold, J.D.1    Kaplan, B.2
  • 3
    • 0029023726 scopus 로고
    • Can overall results of clinical trials be applied to all patients?
    • Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995 345 : 1616 1619.
    • (1995) Lancet , vol.345 , pp. 1616-1619
    • Rothwell, P.M.1
  • 4
    • 12444289440 scopus 로고    scopus 로고
    • Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages
    • Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004 82 : 661 687.
    • (2004) Milbank Q , vol.82 , pp. 661-687
    • Kravitz, R.L.1    Duan, N.2    Braslow, J.3
  • 5
    • 0032401967 scopus 로고    scopus 로고
    • Heterogeneity of the baseline risk within patient populations of clinical trials: A proposed evaluation algorithm
    • Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: A proposed evaluation algorithm. Am J Epidemiol 1998 148 : 1117 1126.
    • (1998) Am J Epidemiol , vol.148 , pp. 1117-1126
    • Ioannidis, J.P.1    Lau, J.2
  • 6
    • 34548575455 scopus 로고    scopus 로고
    • Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification
    • Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 2007 298 : 1209 1212.
    • (2007) JAMA , vol.298 , pp. 1209-1212
    • Kent, D.M.1    Hayward, R.A.2
  • 7
    • 0034712491 scopus 로고    scopus 로고
    • Subgroup analysis and other (mis)uses of baseline data in clinical trials
    • Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000 355 : 1064 1069.
    • (2000) Lancet , vol.355 , pp. 1064-1069
    • Assmann, S.F.1    Pocock, S.J.2    Enos, L.E.3    Kasten, L.E.4
  • 8
    • 0026501239 scopus 로고
    • A consumer's guide to subgroup analyses
    • Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992 116 : 78 84.
    • (1992) Ann Intern Med , vol.116 , pp. 78-84
    • Oxman, A.D.1    Guyatt, G.H.2
  • 9
    • 20544433374 scopus 로고    scopus 로고
    • Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices
    • Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices. Am J Kidney Dis 2005 46 : 136 142.
    • (2005) Am J Kidney Dis , vol.46 , pp. 136-142
    • Jassal, S.V.1    Schaubel, D.E.2    Fenton, S.S.3
  • 10
    • 33746523438 scopus 로고    scopus 로고
    • Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis
    • Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 2006 6 : 18.
    • (2006) BMC Med Res Methodol , vol.6 , pp. 18
    • Hayward, R.A.1    Kent, D.M.2    Vijan, S.3    Hofer, T.P.4
  • 11
    • 0037159557 scopus 로고    scopus 로고
    • An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase
    • Kent DM, Hayward RA, Griffith JL et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 2002 113 : 104 111.
    • (2002) Am J Med , vol.113 , pp. 104-111
    • Kent, D.M.1    Hayward, R.A.2    Griffith, J.L.3
  • 12
    • 34249882718 scopus 로고    scopus 로고
    • Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease
    • Kent DM, Jafar TH, Hayward RA et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007 18 : 1959 1965.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1959-1965
    • Kent, D.M.1    Jafar, T.H.2    Hayward, R.A.3
  • 13
    • 0034107607 scopus 로고    scopus 로고
    • Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?
    • Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus? Diabetologia 2000 43 : 125 130.
    • (2000) Diabetologia , vol.43 , pp. 125-130
    • Vijan, S.1    Kent, D.M.2    Hayward, R.A.3
  • 14
    • 70349197933 scopus 로고    scopus 로고
    • U.S.Food and Drug Administration. Available from
    • U.S.Food and Drug Administration. Xigris product information. Available from : http://www.fda.gov/medwatch/safety/2009/Xigris-PI.pdf 2009
    • (2009) Xigris Product Information
  • 15
    • 34047171006 scopus 로고    scopus 로고
    • Why hasn't eliminating acute rejection improved graft survival?
    • Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 2007 58 : 369 385.
    • (2007) Annu Rev Med , vol.58 , pp. 369-385
    • Tantravahi, J.1    Womer, K.L.2    Kaplan, B.3
  • 16
    • 0034667904 scopus 로고    scopus 로고
    • Increased impact of acute rejection on chronic allograft failure in recent era
    • Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000 70 : 1098 1100.
    • (2000) Transplantation , vol.70 , pp. 1098-1100
    • Meier-Kriesche, H.U.1    Ojo, A.O.2    Hanson, J.A.3
  • 17
    • 0006986048 scopus 로고    scopus 로고
    • A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
    • A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996 61 : 1029 1037.
    • (1996) Transplantation , vol.61 , pp. 1029-1037
  • 18
    • 0032526253 scopus 로고    scopus 로고
    • A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
    • Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998 65 : 1450 1454.
    • (1998) Transplantation , vol.65 , pp. 1450-1454
    • Mathew, T.H.1
  • 19
    • 33748698619 scopus 로고    scopus 로고
    • Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial
    • Hazzan M, Buob D, Labalette M et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006 82 : 657 662.
    • (2006) Transplantation , vol.82 , pp. 657-662
    • Hazzan, M.1    Buob, D.2    Labalette, M.3
  • 20
    • 0345099476 scopus 로고    scopus 로고
    • Graft survival benefit to be expected of new immunosuppressive regimens
    • Ekberg H. Graft survival benefit to be expected of new immunosuppressive regimens. Transplant Rev 2003 17 : 187 193.
    • (2003) Transplant Rev , vol.17 , pp. 187-193
    • Ekberg, H.1
  • 21
    • 34248136067 scopus 로고    scopus 로고
    • The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage
    • Aydingoz SE, Takemoto SK, Pinsky BW et al. The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage. Hum Immunol 2007 68 : 491 499.
    • (2007) Hum Immunol , vol.68 , pp. 491-499
    • Aydingoz, S.E.1    Takemoto, S.K.2    Pinsky, B.W.3
  • 22
    • 0025981730 scopus 로고
    • Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients
    • Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991 51 : 338 342.
    • (1991) Transplantation , vol.51 , pp. 338-342
    • Kerman, R.H.1    Kimball, P.M.2    Van Buren, C.T.3    Lewis, R.M.4    Kahan, B.D.5
  • 23
    • 0022500581 scopus 로고
    • Multivariate analysis of risk factors in cadaver donor kidney transplantation
    • Sanfilippo F, Vaughn WK, LeFor WM, Spees EK. Multivariate analysis of risk factors in cadaver donor kidney transplantation. Transplantation 1986 42 : 28 34.
    • (1986) Transplantation , vol.42 , pp. 28-34
    • Sanfilippo, F.1    Vaughn, W.K.2    Lefor, W.M.3    Spees, E.K.4
  • 24
    • 0031930886 scopus 로고    scopus 로고
    • Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin
    • Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998 13 : 711 715.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 711-715
    • Thibaudin, D.1    Alamartine, E.2    De Filippis, J.P.3    Diab, N.4    Laurent, B.5    Berthoux, F.6
  • 26
    • 10844292763 scopus 로고    scopus 로고
    • Immunosuppressive drugs for kidney transplantation. [erratum appears in N Engl J Med 2005;352:1056]. [review] [124 refs]
    • Halloran PF. Immunosuppressive drugs for kidney transplantation. [erratum appears in N Engl J Med 2005;352:1056]. [Review] [124 refs]. N Engl J Med 2004 351 : 2715 2729.
    • (2004) N Engl J Med , vol.351 , pp. 2715-2729
    • Halloran, P.F.1
  • 27
    • 70349213699 scopus 로고    scopus 로고
    • Cardiac events post kidney transplantation: Interim results from the patient outcomes in renal transplantation (PORT) international transplant study
    • Ref Type: Abstract
    • Kasiske BL, Israni AK, Snyder JJ, Skeans MA, Weinhandl ED, Peng Y. Cardiac events post kidney transplantation: Interim results from the patient outcomes in renal transplantation (PORT) international transplant study. Am J Transplant 2008 8 s2 177 336. Ref Type: Abstract
    • (2008) Am J Transplant , vol.8 , Issue.S2 , pp. 177-336
    • Kasiske, B.L.1    Israni, A.K.2    Snyder, J.J.3    Skeans, M.A.4    Weinhandl, E.D.5    Peng, Y.6
  • 29
    • 4444333174 scopus 로고    scopus 로고
    • Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors
    • Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004 57 : 683 697.
    • (2004) J Clin Epidemiol , vol.57 , pp. 683-697
    • Schmid, C.H.1    Stark, P.C.2    Berlin, J.A.3    Landais, P.4    Lau, J.5
  • 30
    • 70349221221 scopus 로고    scopus 로고
    • Twelve-month results of a multicenter, randomized trial comparing three induction agents (Alemtuzumab, Thymoglobulin and Basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation
    • Hanaway M, Woodle SE, Mulgaonkar S et al. Twelve-month results of a multicenter, randomized trial comparing three induction agents (Alemtuzumab, Thymoglobulin and Basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation. Am J Transplant 2008 8 : 177 336.
    • (2008) Am J Transplant , vol.8 , pp. 177-336
    • Hanaway, M.1    Woodle, S.E.2    Mulgaonkar, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.